1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
- 2014
-
Mark
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(
- Contribution to journal › Scientific review
- 2009
-
Mark
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
(
- Contribution to journal › Scientific review
-
Mark
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
(
- Contribution to journal › Scientific review
-
Mark
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
(
- Contribution to journal › Article
- 2008
-
Mark
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
(
- Contribution to journal › Article